Understanding HIV drug resistance in Nigerian children on dolutegravir
Official title: Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientists
Funded at Brigham and Women's Hospital · NIH-11057687 · Data updated 2026-11-12
This study is looking at why some children in Nigeria aren't responding well to the HIV medicine dolutegravir, and it aims to create a quick test to help doctors spot any resistance to the treatment early on, so they can provide better care for these kids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 18, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $418,170 |
| NIH project number | 5R01AI184118-02 |
| Project ID | NIH-11057687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are Nigerian children who are currently failing dolutegravir treatment and have detectable levels of the virus.
✕Less likely to help
Patients who are not on dolutegravir or those who are not experiencing treatment failure may not benefit from this research.
What this research studies
This research investigates how some children in Nigeria develop resistance to the HIV medication dolutegravir. By studying a group of children who are not responding well to this treatment, the researchers aim to identify the presence of integrase resistance, which can hinder effective HIV management. The study will involve collecting data on these children's health and viral loads, and using this information to create a rapid diagnostic test that can help in identifying resistance early. This collaboration with Nigerian scientists aims to address a critical gap in knowledge regarding HIV treatment in children.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools for detecting HIV drug resistance in children, improving treatment outcomes.
How similar studies have gone: Previous research has indicated the presence of drug resistance in adults on dolutegravir, suggesting that this approach could yield valuable insights for children as well.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Rawizza, Holly Elizabeth — Brigham and Women's Hospital
- Study coordinator: Rawizza, Holly Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.